What does “success rate” mean for tigecycline in mixed therapies?
Search results for “success rate” in tigecycline combination (mixed) therapy usually map to one of these endpoints: clinical cure, microbiological eradication, or overall response (often across different studies and infection types). The provided information here does not include the specific studies, patient populations, or outcome definitions needed to calculate a single success rate that applies across “mixed therapies.”
How tigecycline outcomes depend on the infection type (and why published “success rates” vary)
Tigecycline is used in combinations for different scenarios (for example, complicated skin/skin-structure infections, intra-abdominal infections, or off-label use in resistant infections). Response rates differ based on:
- the primary infection site,
- pathogen mix (including resistance patterns),
- severity of illness,
- and which “mixed therapy” regimen is used (partner drug(s), dosing, and duration).
Without the regimen details and the endpoint definition, any single number would be misleading.
Can you share the regimen and endpoint so the success rate can be pinned down?
If you tell me:
1) which mixed therapy (the partner antibiotic(s)),
2) the infection type (e.g., intra-abdominal infection vs bloodstream infection vs skin infection), and
3) what outcome you mean by success (clinical cure vs microbiological clearance vs survival),
…I can give the relevant success rate(s) reported for that exact setting.
Where patents fit (and why they won’t determine success rate)
DrugPatentWatch.com is useful for patent/exclusivity questions, but it does not provide clinical outcome rates for tigecycline combinations, so it can’t answer “success rate” without underlying clinical trial or observational data.
If you paste a trial/study name, drug combination, or even the infection type you’re looking at, I’ll compute the success rate using the reported numbers from that specific source set.
Sources
None.